Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape

Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape

Multiple myeloma (MM) continues to be an incurable disease impacting mainly an ageing population. Comorbidities, disease characteristics, and drug toxicity profiles heavily influence treatment selections. Despite single agent activity of many anti-MM agents, opportunities to maintain responses most...

Full description

Bibliographic Details
Main Authors: Rebecca Gonzalez, Hanna Bailey, Omar Castaneda Puglianini
Format: Article
Language:English
Published: European Medical Journal 2021-07-01
Series:European Medical Journal Nephrology
Subjects:
b-cell maturation antigen (bcma)
belantamab mafodotin
cd38
immunotherapy
isatuximab
monoclonal antibodies
multiple myeloma (mm)
Online Access:https://www.emjreviews.com/hematology/article/isatuximab-and-belantamab-mafodotin-a-primer-to-an-evolving-multiple-myeloma-landscape/

Internet

https://www.emjreviews.com/hematology/article/isatuximab-and-belantamab-mafodotin-a-primer-to-an-evolving-multiple-myeloma-landscape/

Similar Items